{"title":"P-glycoprotein Expressing-B cell associated Active True Renal Lupus Vasculitis in Lupus Nephritis","authors":"S. Tsujimura, Akio Kawabe, Yoshiya Tanaka","doi":"10.35248/2684-1630.20.5.150","DOIUrl":null,"url":null,"abstract":"True renal lupus vasculitis (TRLV), a rare form of vascular lesion usually associated with proliferative lupus nephritis \n(LN), is resistant to conventional treatments and associated with poor renal outcome among renal vasculopathies. \nEvidence suggests the involvement of P-glycoprotein (P-gp) expressing-activated B cells in the pathogenesis and \ntreatment resistance of TRLV through the production of autoantibodies and direct infiltration into the inflammatory \nlesion of small vessels. Therapies targeting activated B cells might overcome refractory TRLV. Identification of \nthe subsets of peripheral activated B cells that express P-gp in TRLV patients might help the selection of suitable \ntreatment strategy.","PeriodicalId":139271,"journal":{"name":"Lupus: Open Access","volume":"73 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lupus: Open Access","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.35248/2684-1630.20.5.150","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2
Abstract
True renal lupus vasculitis (TRLV), a rare form of vascular lesion usually associated with proliferative lupus nephritis
(LN), is resistant to conventional treatments and associated with poor renal outcome among renal vasculopathies.
Evidence suggests the involvement of P-glycoprotein (P-gp) expressing-activated B cells in the pathogenesis and
treatment resistance of TRLV through the production of autoantibodies and direct infiltration into the inflammatory
lesion of small vessels. Therapies targeting activated B cells might overcome refractory TRLV. Identification of
the subsets of peripheral activated B cells that express P-gp in TRLV patients might help the selection of suitable
treatment strategy.